{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T21:22:56Z","timestamp":1773350576047,"version":"3.50.1"},"reference-count":48,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T00:00:00Z","timestamp":1705622400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.vaccine.2024.01.052","type":"journal-article","created":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T12:11:07Z","timestamp":1706184667000},"page":"1168-1178","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Determinants of SARS-CoV-2 IgG response and decay in Canadian healthcare workers: A prospective cohort study"],"prefix":"10.1016","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3147-1548","authenticated-orcid":false,"given":"Nicola","family":"Cherry","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4973-8474","authenticated-orcid":false,"given":"Anil","family":"Adisesh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Igor","family":"Burstyn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9129-5136","authenticated-orcid":false,"given":"Carmen","family":"Charlton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1168-4201","authenticated-orcid":false,"given":"Quentin","family":"Durand-Moreau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"France","family":"Labr\u00e8che","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shannon","family":"Ruzycki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2786-3087","authenticated-orcid":false,"given":"LeeAnn","family":"Turnbull","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3564-8478","authenticated-orcid":false,"given":"Tanis","family":"Zadunayski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Yasui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"27","key":"10.1016\/j.vaccine.2024.01.052_b0005","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.vaccine.2024.01.052_b0010","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.vaccine.2024.01.052_b0015","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1056\/NEJMoa2110345","article-title":"Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine through 6 months","volume":"385","author":"Thomas","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.vaccine.2024.01.052_b0020","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1056\/NEJMoa2115463","article-title":"Comparative effectiveness of BNT162b2 and mRNA-1273 vaccines in U.S","volume":"386","author":"Dickerman","year":"2022","journal-title":"Veterans N Engl J Med"},{"issue":"24","key":"10.1016\/j.vaccine.2024.01.052_b0025","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1056\/NEJMoa2114114","article-title":"Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar","volume":"385","author":"Chemaitelly","year":"2021","journal-title":"N Engl J Med"},{"issue":"10309","key":"10.1016\/j.vaccine.2024.01.052_b0030","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S0140-6736(21)02183-8","article-title":"Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study","volume":"398","author":"Tartof","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2024.01.052_b0035","doi-asserted-by":"crossref","first-page":"1021396","DOI":"10.3389\/fimmu.2022.1021396","article-title":"Evaluation of humoral and cellular response to four vaccines against COVID-19 in different age groups: a longitudinal study","volume":"13","author":"Fedele","year":"2022","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.vaccine.2024.01.052_b0040","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/S2213-2600(21)00220-4","article-title":"BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers","volume":"9","author":"Lustig","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"2","key":"10.1016\/j.vaccine.2024.01.052_b0045","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3390\/vaccines10020285","article-title":"Modelling SARS-CoV-2 binding antibody waning 8 months after BNT162b2 vaccination","volume":"10","author":"Hatzakis","year":"2022","journal-title":"Vaccines (Basel)"},{"issue":"12","key":"10.1016\/j.vaccine.2024.01.052_b0050","doi-asserted-by":"crossref","first-page":"e12125","DOI":"10.1016\/j.heliyon.2022.e12125","article-title":"Dynamics of anti-spike IgG antibody after a third BNT162b2 COVID-19 vaccination in Japanese health care workers","volume":"8","author":"Ikezaki","year":"2022","journal-title":"Heliyon"},{"issue":"5","key":"10.1016\/j.vaccine.2024.01.052_b0055","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.3390\/microorganisms11051279","article-title":"Age, sex and BMI relations with anti-SARS-CoV-2-Spike IgG antibodies after BNT162b2 COVID-19 vaccine in health care workers in Northern Greece","volume":"11","author":"Papaioannidou","year":"2023","journal-title":"Microorganisms"},{"issue":"7","key":"10.1016\/j.vaccine.2024.01.052_b0060","doi-asserted-by":"crossref","first-page":"ofad266","DOI":"10.1093\/ofid\/ofad266","article-title":"Kinetics of SARS-CoV-2 serum antibodies through the alpha, delta, and omicron surges among vaccinated health care workers at a Boston hospital","volume":"10","author":"Dodge","year":"2023","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2024.01.052_b0065","doi-asserted-by":"crossref","first-page":"7711","DOI":"10.1038\/s41467-022-35480-2","article-title":"Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-up","volume":"13","author":"Canetti","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2024.01.052_b0070","doi-asserted-by":"crossref","first-page":"e068632","DOI":"10.1136\/bmj-2021-068632","article-title":"Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis","volume":"376","author":"Lee","year":"2022","journal-title":"BMJ"},{"issue":"7","key":"10.1016\/j.vaccine.2024.01.052_b0075","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1111\/1756-185X.14713","article-title":"Immunogenicity of COVID-19 vaccines in adult patients with autoimmune inflammatory rheumatic diseases: a systematic review and meta-analysis","volume":"26","author":"Al-Haideri","year":"2023","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.vaccine.2024.01.052_b0080","article-title":"Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies","volume":"14","author":"Achiron","year":"2021","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.vaccine.2024.01.052_b0085","first-page":"kead275","article-title":"Immunosuppressive therapy and humoral response to third mRNA COVID-19 vaccination with a six-month interval in rheumatic disease patients","author":"Kashiwado","year":"2023","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.vaccine.2024.01.052_b0090","doi-asserted-by":"crossref","first-page":"e3465","DOI":"10.1002\/dmrr.3465","article-title":"Central obesity, smoking habit, and hypertension are associated with lower antibody titres in response to COVID-19 mRNA vaccine","volume":"38","author":"Watanabe","year":"2022","journal-title":"Diabetes Metab Res Rev"},{"issue":"5","key":"10.1016\/j.vaccine.2024.01.052_b0095","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1002\/uog.26050","article-title":"Evaluation of immunogenicity and reactogenicity of COVID-19 vaccines in pregnant women","volume":"60","author":"Blakeway","year":"2022","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"8","key":"10.1016\/j.vaccine.2024.01.052_b0100","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.3390\/vaccines10081220","article-title":"Correlation between adverse events and antibody titers among healthcare workers vaccinated with BNT162b2 mRNA COVID-19 vaccine","volume":"10","author":"Levy","year":"2022","journal-title":"Vaccines (Basel)"},{"issue":"1","key":"10.1016\/j.vaccine.2024.01.052_b0105","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/imr.13089","article-title":"Immunological memory to SARS-CoV-2 infection and COVID-19 vaccines","volume":"310","author":"Sette","year":"2022","journal-title":"Immunol Rev"},{"issue":"11","key":"10.1016\/j.vaccine.2024.01.052_b0110","doi-asserted-by":"crossref","first-page":"e074716","DOI":"10.1136\/bmjopen-2023-074716","article-title":"Cohort profile: recruitment and retention in a prospective cohort of Canadian health care workers during the COVID-19 pandemic","volume":"13","author":"Cherry","year":"2023","journal-title":"BMJ Open"},{"key":"10.1016\/j.vaccine.2024.01.052_b0115","unstructured":"World Health Organization. International classification of diseases 11th revision. Available on: https:\/\/icd.who.int\/en (accessed on 11 August 2023); 2020."},{"key":"10.1016\/j.vaccine.2024.01.052_b0120","doi-asserted-by":"crossref","first-page":"e44465","DOI":"10.2196\/44465","article-title":"Accuracy of self-reported COVID-19 vaccination status compared with a public health vaccination registry in Qu\u00e9bec: observational diagnostic study","volume":"9","author":"Archambault","year":"2023","journal-title":"JMIR Public Health Surveill"},{"issue":"6","key":"10.1016\/j.vaccine.2024.01.052_b0125","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1111\/irv.13023","article-title":"Ascertainment of vaccination status by self-report versus source documentation: impact on measuring COVID-19 vaccine effectiveness","volume":"16","author":"Stephenson","year":"2022","journal-title":"Influenza Other Respi Viruses"},{"issue":"1","key":"10.1016\/j.vaccine.2024.01.052_b0130","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3390\/vaccines10010064","article-title":"Large-scale study of antibody titer decay following BNT162b2 mRNA vaccine or SARS-CoV-2 infection","volume":"10","author":"Israel","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2024.01.052_b0135","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ijid.2022.07.053","article-title":"Nucleocapsid and spike antibody responses following virologically confirmed SARS-CoV-2 infection: an observational analysis in the Virus Watch community cohort","volume":"123","author":"Navaratnam","year":"2022","journal-title":"Int J Infect Dis"},{"issue":"15","key":"10.1016\/j.vaccine.2024.01.052_b0140","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1001\/jama.2021.15125","article-title":"Comparison of SARS-CoV-2 antibody response following vaccination with BNT162b2 and mRNA-1273","volume":"326","author":"Steensels","year":"2021","journal-title":"J Am Med Assoc"},{"issue":"5","key":"10.1016\/j.vaccine.2024.01.052_b0145","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1038\/s41591-022-01721-6","article-title":"Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines","volume":"28","author":"Wei","year":"2022","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.vaccine.2024.01.052_b0150","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jinf.2021.12.035","article-title":"Short-term effectiveness of COVID-19 vaccines in immunocompromised patients: a systematic literature review and meta-analysis","volume":"84","author":"Marra","year":"2022","journal-title":"J Infect"},{"issue":"44","key":"10.1016\/j.vaccine.2024.01.052_b0155","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.15585\/mmwr.mm7044e3","article-title":"Effectiveness of 2-dose vaccination with mRNA COVID-19 vaccines against COVID-19\u2013associated hospitalizations among immunocompromised adults \u2014 nine states, January\u2013September 2021","volume":"70","author":"Embi","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"11","key":"10.1016\/j.vaccine.2024.01.052_b0160","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1038\/s41591-021-01507-2","article-title":"Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy","volume":"27","author":"Apostolidis","year":"2021","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.vaccine.2024.01.052_b0165","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1177\/13524585231185246","article-title":"Vaccine-breakthrough SARS-CoV-2 infections in people with multiple sclerosis and related conditions: an observational study by the New York COVID-19 Neuro-Immunology Consortium (NYCNIC-2)","volume":"29","author":"Klineova","year":"2023","journal-title":"Mult Scler"},{"issue":"26","key":"10.1016\/j.vaccine.2024.01.052_b0170","doi-asserted-by":"crossref","first-page":"3862","DOI":"10.1016\/j.vaccine.2023.05.012","article-title":"Anti-tumor necrosis factor therapy is associated with attenuated humoral response to SARS-COV-2 vaccines in patients with inflammatory bowel disease","volume":"41","author":"Bordalo Ferreira","year":"2023","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2024.01.052_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100350","article-title":"Antineoplastic treatment class modulates COVID-19 mRNA-BNT162b2 vaccine immunogenicity in cancer patients: a secondary analysis of the prospective Vax-On study","volume":"7","author":"Ruggeri","year":"2022","journal-title":"ESMO Open"},{"issue":"9","key":"10.1016\/j.vaccine.2024.01.052_b0180","doi-asserted-by":"crossref","first-page":"e0257668","DOI":"10.1371\/journal.pone.0257668","article-title":"Does reactogenicity after a second injection of the BNT162b2 vaccine predict spike IgG antibody levels in healthy Japanese subjects?","volume":"16","author":"Takeuchi","year":"2021","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.vaccine.2024.01.052_b0185","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.3904\/kjim.2021.210","article-title":"Can reactogenicity predict immunogenicity after COVID-19 vaccination?","volume":"36","author":"Hwang","year":"2021","journal-title":"Korean J Intern Med"},{"issue":"11","key":"10.1016\/j.vaccine.2024.01.052_b0190","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1007\/s40520-021-01987-9","article-title":"Does a lack of vaccine side effects correlate with reduced BNT162b2 mRNA vaccine response among healthcare workers and nursing home residents?","volume":"33","author":"Oyebanji","year":"2021","journal-title":"Aging Clin Exp Res"},{"key":"10.1016\/j.vaccine.2024.01.052_b0195","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41541-019-0132-6","article-title":"The how's and what's of vaccine reactogenicity","volume":"4","author":"Herv\u00e9","year":"2019","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.vaccine.2024.01.052_b0200","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.coi.2017.06.009","article-title":"No pain no gain? Adjuvant effects of alum and monophosphoryl lipid A in pertussis and HPV vaccines","volume":"47","author":"Mitchell","year":"2017","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.vaccine.2024.01.052_b0205","doi-asserted-by":"crossref","first-page":"943","DOI":"10.3389\/fimmu.2017.00943","article-title":"Different adjuvants induce common innate pathways that are associated with enhanced adaptive responses against a model antigen in humans","volume":"8","author":"Burny","year":"2017","journal-title":"Front Immunol"},{"issue":"23","key":"10.1016\/j.vaccine.2024.01.052_b0210","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1001\/jama.2021.7563","article-title":"Immunogenicity of COVID-19 mRNA vaccines in pregnant and lactating women","volume":"325","author":"Collier","year":"2021","journal-title":"J Am Med Assoc"},{"issue":"3","key":"10.1016\/j.vaccine.2024.01.052_b0215","doi-asserted-by":"crossref","first-page":"303.e1","DOI":"10.1016\/j.ajog.2021.03.023","article-title":"Coronavirus disease 2019 vaccine response in pregnant and lactating women: a cohort study","volume":"225","author":"Gray","year":"2021","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"10.1016\/j.vaccine.2024.01.052_b0220","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1038\/s41467-022-31169-8","article-title":"Maternal immune response and placental antibody transfer after COVID-19 vaccination across trimester and platforms","volume":"13","author":"Atyeo","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2024.01.052_b0225","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.839922","article-title":"Persistence of immune response in health care workers after two doses BNT162b2 in a longitudinal observational study","volume":"13","author":"Herzberg","year":"2022","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2024.01.052_b0230","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/oby.23353","article-title":"Antibody responses to BNT162b2 mRNA vaccine: infection-na\u00efve individuals with abdominal obesity warrant attention","volume":"30","author":"Malavazos","year":"2022","journal-title":"Obesity (Silver Spring)"},{"issue":"5","key":"10.1016\/j.vaccine.2024.01.052_b0235","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1038\/s41591-023-02343-2","article-title":"Accelerated waning of the humoral response to COVID-19 vaccines in obesity","volume":"29","author":"van der Klaauw","year":"2023","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.vaccine.2024.01.052_b0240","doi-asserted-by":"crossref","first-page":"e13078","DOI":"10.1111\/irv.13078","article-title":"Antibody responses to COVID-19 vaccination in people with obesity: a systematic review and meta-analysis","volume":"17","author":"Ou","year":"2023","journal-title":"Influenza Other Respi Viruses"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24000641?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24000641?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:34:01Z","timestamp":1759404841000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X24000641"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":48,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S0264410X24000641"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.01.052","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.09.12.23295445","asserted-by":"object"}]},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Determinants of SARS-CoV-2 IgG response and decay in Canadian healthcare workers: A prospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.01.052","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}